| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | http://www.brookslabs.net | |
| Market Cap | 258.98 Cr. | |
| Enterprise Value(EV) | 267.23 Cr. | 2023-09 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | -5.44 | Trailing Twelve Months Ending 2023-12 |
| Price-Earning Ratio (PE) | - | Trailing Twelve Months Ending 2023-12 |
| Industry PE | 41.01 | Trailing Twelve Months Ending 2023-12 |
| Book Value / Share | 30.36 | Trailing Twelve Months Ending 2023-12 |
| Price to Book Value | 3.25 | Calculated using Price: 98.67 |
| Dividend Yield | 0.00 | Period Ending 2023-03 |
| No. of Shares Subscribed | 2.62 Cr. | 26,246,738 Shares |
| FaceValue | 10 | |
| About Brooks Laboratories Ltd. | ||
| The Company was originally incorporated as Brooks Laboratories Limited on January 23, 2002. Company was initially promoted for manufacturing of latest molecules in Injectables, tablets and dry syrups for the domestic customers. The Company set up a facility for manufacturing Tablets, Dry Syrup and Injectables, which was supported by a research and development centre at Baddi, Himachal Pradesh. The Company started its commercial production in the month of June 2006 and became profitable from the very first year of its production. | ||
| 1 Day |
|
-2.00% |
| 1 Week |
|
-7.13% |
| 1 Month |
|
-5.12% |
| 3 Month |
|
-35.64% |
| 6 Month |
|
-15.92% |
| 1 Year |
|
+48.42% |
| 2 Year |
|
+8.11% |
| 5 Year |
|
+117.05% |
| 10 Year |
|
+492.26% |
| 3 years | 2021-03 | 2022-03 | 2023-03 | |
| Return on Equity (%) | -24.48 | -23.18 | -38.47 | |
| Return on Capital Employed (%) | -5.33 | -18.72 | -37.84 | |
| Return on Assets (%) | -11.95 | -10.83 | -20.42 |
| Particulars | 4 years | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
| Shh. Funds | 79 | 87 | 74 | 79 | |
| Non Curr. Liab. | 19 | 11 | 3 | 3 | |
| Curr. Liab. | 64 | 49 | 33 | 24 | |
| Minority Int. | 47 | ||||
| Equity & Liab. | 162 | 195 | 110 | 106 | |
| Non Curr. Assets | 112 | 133 | 82 | 76 | |
| Curr. Assets | 47 | 61 | 28 | 30 | |
| Misc. Exp. not W/O | |||||
| Total Assets | 162 | 195 | 110 | 106 |
| Particulars | 4 years | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-12 Rs. Cr. TTM |
| Net Sales | 77 | 91 | 63 | 74 | |
| Other Income | 1 | 1 | 0 | 0 | |
| Total Income | 78 | 92 | 63 | 75 | |
| Total Expenditure | -77 | -105 | -90 | -72 | |
| PBIDT | 1 | -13 | -26 | 3 | |
| Interest | -3 | -3 | -2 | -1 | |
| Depreciation | -7 | -7 | -7 | -2 | |
| Taxation | -10 | 5 | 7 | 0 | |
| Exceptional Items | 0 | ||||
| PAT | -19 | -19 | -31 | 1 | |
| Minority Interest | 8 | 10 | |||
| Share Associate | -15 | ||||
| Other Related Items | |||||
| Consolidated Net Profit | -19 | -11 | -21 | -14 | |
| Adjusted EPS | -8 | -5 | -8 | -6 |
| Particulars | 3 years | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
| Cash Fr. Operatn. | 4 | -37 | -14 | |
| Cash Fr. Inv. | -5 | -25 | 0 | |
| Cash Fr. Finan. | 1 | 64 | 11 | |
| Net Change | 0 | 2 | -3 | |
| Cash & Cash Eqvt | 1 | 3 | 0 |
|
Fri, 19 Apr 2024
Certificate Under Regulation 40(9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 For Financial Year Ended 31.03.2024. Certificate under Regulation 40(9) of SEBI (LODR) Regulation 2015 for financial year ended 31.03.2024. |
|
Fri, 19 Apr 2024
Certificate Under Regulation 40(9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 For Financial Year Ended 31.03.2024 Certificate under Regulation 40(9) of SEBI (LODR) Regulation 2015 for Financial year ended 31.03.2024 |
|
Wed, 10 Apr 2024
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 Compliance Certificate under Regulation 74(5) of SEBI (DP) Regulation 2018 for quarter ended March 31 2024 |
| Thu, 18 Apr 2024 |
Opening at High
|
Opening at High for 3 days
|
Closing Below Previous Low
|
Opening at High for 2 Days
|
Closing Below Previous Low for 2 Days
|
